MX2021002994A - Usos de inhibidores del inhibidor del activador de plasminogeno tipo 1 (pai-1). - Google Patents

Usos de inhibidores del inhibidor del activador de plasminogeno tipo 1 (pai-1).

Info

Publication number
MX2021002994A
MX2021002994A MX2021002994A MX2021002994A MX2021002994A MX 2021002994 A MX2021002994 A MX 2021002994A MX 2021002994 A MX2021002994 A MX 2021002994A MX 2021002994 A MX2021002994 A MX 2021002994A MX 2021002994 A MX2021002994 A MX 2021002994A
Authority
MX
Mexico
Prior art keywords
alopecia
prevention
treatment
pai
inhibitors
Prior art date
Application number
MX2021002994A
Other languages
English (en)
Inventor
Jonathan Edelson
Original Assignee
Eirion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eirion Therapeutics Inc filed Critical Eirion Therapeutics Inc
Publication of MX2021002994A publication Critical patent/MX2021002994A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/002—Magnetotherapy in combination with another treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/067—Radiation therapy using light using laser light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0023—Drug applicators using microneedles

Abstract

La presente descripción proporciona información sorprendente sobre nuevas tecnologías para el tratamiento y/o prevención de ciertos tipos de pérdida de cabello (también conocida como alopecia), incluidas alopecia androgenética, alopecia areata, alopecia fibrosante frontal y alopecia senescente. Entre otras cosas, la presente descripción proporciona una percepción sorprendente de que los inhibidores del inhibidor del activador de plasminógeno tipo 1 (PAI-1) pueden ser sorprendentemente efectivos y/o útiles en el tratamiento y/o prevención de ciertos tipos de pérdida de cabello, incluidas alopecia androgenética, alopecia areata, alopecia fibrosante frontal y alopecia senescente. Adicionalmente, la presente descripción proporciona la percepción de que las nuevas tecnologías proporcionadas pueden no ser particularmente efectivas y/o útiles en el tratamiento y/o prevención de otros tipos de alopecia tal como alopecia inducida por radiación, alopecia inducida por quimioterapia y alopecia debida a lupus eritematoso discoide crónico.
MX2021002994A 2018-09-13 2019-09-12 Usos de inhibidores del inhibidor del activador de plasminogeno tipo 1 (pai-1). MX2021002994A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731076P 2018-09-13 2018-09-13
PCT/US2019/050890 WO2020056191A1 (en) 2018-09-13 2019-09-12 Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors

Publications (1)

Publication Number Publication Date
MX2021002994A true MX2021002994A (es) 2021-07-15

Family

ID=68073184

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002994A MX2021002994A (es) 2018-09-13 2019-09-12 Usos de inhibidores del inhibidor del activador de plasminogeno tipo 1 (pai-1).

Country Status (12)

Country Link
US (1) US20220079911A1 (es)
EP (1) EP3849540A1 (es)
JP (1) JP2022500452A (es)
KR (1) KR20210057140A (es)
CN (1) CN113056269A (es)
AU (1) AU2019339488A1 (es)
BR (1) BR112021004550A2 (es)
CA (1) CA3112549A1 (es)
IL (1) IL281451A (es)
MX (1) MX2021002994A (es)
SG (1) SG11202102479TA (es)
WO (1) WO2020056191A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110198703A (zh) 2016-11-21 2019-09-03 艾里奥治疗公司 大试剂的透皮递送

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US296006A (en) 1884-04-01 John hoefleb
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1261849B (it) 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
US6461596B1 (en) * 1997-02-18 2002-10-08 Andrea Taylor Composition and method for promoting hair growth
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US5965154A (en) 1998-03-17 1999-10-12 Plc Holding, L.L.C. Adhesive matrix type transdermal patch and method of manufacturing same
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
US6611707B1 (en) 1999-06-04 2003-08-26 Georgia Tech Research Corporation Microneedle drug delivery device
US6908453B2 (en) 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
CA2476761A1 (en) * 2002-02-19 2003-08-28 Vanderbilt University Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors
AU2003301809A1 (en) * 2002-05-13 2004-06-07 Children's Hospital Los Angeles Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions
EP3144013B1 (en) 2005-12-01 2018-11-14 University Of Massachusetts Lowell Botulinum nanoemulsions
WO2008039245A2 (en) 2006-04-27 2008-04-03 Anterios, Inc. Assessment of the effects of topical administration of chemodenervating pharmaceuticals
CN101848702B (zh) 2006-12-01 2013-07-17 安特里奥公司 两亲实体纳米粒子
BRPI0914630A2 (pt) 2008-06-26 2019-09-24 Anterios Inc liberação dérmica
TR201905477T4 (tr) 2011-01-24 2019-05-21 Anterios Inc Nano-parçacık bileşimler.
AU2012209274A1 (en) 2011-01-24 2013-09-12 Anterios, Inc. Nanoparticle compositions, formulations thereof, and uses therefor
EP2793869B1 (en) 2011-12-21 2015-09-23 3M Innovative Properties Company Transdermal adhesive patch assembly with removable microneedle array and method of using same
CN103479627A (zh) * 2013-05-16 2014-01-01 武汉光谷百桥国际生物科技有限公司 一种血管紧张素ii的i型受体拮抗剂在促进毛发生长方面的应用
JP6915946B2 (ja) * 2014-10-29 2021-08-11 サムソン クリニカル プロプライエタリー リミテッド 過剰な毛髪脱落の検出及び処置

Also Published As

Publication number Publication date
US20220079911A1 (en) 2022-03-17
KR20210057140A (ko) 2021-05-20
AU2019339488A1 (en) 2021-04-08
CA3112549A1 (en) 2020-03-19
CN113056269A (zh) 2021-06-29
WO2020056191A1 (en) 2020-03-19
BR112021004550A2 (pt) 2021-06-08
JP2022500452A (ja) 2022-01-04
SG11202102479TA (en) 2021-04-29
IL281451A (en) 2021-04-29
EP3849540A1 (en) 2021-07-21

Similar Documents

Publication Publication Date Title
ZA202007007B (en) Mcl-1 inhibitors
PH12020550622A1 (en) Kras g12c inhibitors
PH12019502258A1 (en) Isoquinolines as inhibitors of hpk1
MY196582A (en) PD-1/PD-L1 Inhibitors
PH12021500005A1 (en) Sulfonimidamide compounds as inhibitors of interleukin-1 activity
MX2018013983A (es) Inhibidores g12c de kras.
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG10201811454WA (en) Materials and methods for controlling infections
MX2019007234A (es) Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2 y metodos de uso de los mismos.
ZA201701460B (en) Gamma-diketones for treatment and prevention of aging skin and wrinkles
TN2018000276A1 (en) Inhibitors of receptor-interacting protein kinase 1.
MX2020009256A (es) Compuestos para el tratamiento de cancer.
MY185579A (en) Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
AU2020258568A8 (en) CD73 inhibitors
NZ756936A (en) Composition and method for preventing or delaying onset of myopia comprising atropine
MX2019008124A (es) Metodos para el tratamiento de trastornos neurologicos.
MX2021002994A (es) Usos de inhibidores del inhibidor del activador de plasminogeno tipo 1 (pai-1).
MX2021002995A (es) Inhibidores del inhibidor 1 de activador de plasminogeno (pai-1) y usos de los mismos.
JOP20190129B1 (ar) تركيبات وطرق تتعلق بمواد مساعدة لـ 5-ht1f من بيريدينويل بيبريدين
NZ743894A (en) Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced hypothermia
MX2021012739A (es) Retrasar el efecto pico y/o prolongar la duracion de la respuesta.
MX2020012805A (es) Compuestos para el tratamiento del dolor, composiciones que comprenden los mismos, y metodos para utilizar los mismos.
MX2022000783A (es) Inhibidores de la ferroportina para el uso en la prevencion y el tratamiento de lesiones renales.
NZ750150A (en) Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors